William Blair Starts Coverage on Qiagen

Brian Weinstein expressed concern about competition in the HPV space and a stock that has tracked the overall market since 2007, but gave a thumbs up to the $355 acquisition of Cellestis.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.